宫颈癌肝转移预后影响因素的研究进展
Research Progress on Prognostic Factors of Hepatic Metastasis from Cervical Cancer
DOI: 10.12677/acm.2026.1693019, PDF,   
作者: 张金怡:西安医学院研究生院,陕西 西安;姜向阳*:陕西省人民医院妇科,陕西 西安
关键词: 宫颈癌;肝转移;预后;影响因素;Cervical Cancer; Hepatic Metastasis; Prognosis; Influencing Factors
摘要: 宫颈癌是全球女性生殖系统中最常见的恶性肿瘤之一,其发病率和死亡率均位居首位,对女性健康构成严重威胁。宫颈癌肝转移虽属罕见的远处转移事件,但多发生于疾病晚期或治疗后复发阶段,因起病隐匿、进展迅速、治疗难度大、预后极差,成为临床管理中的重点和难点。早期识别高危人群、及时实施个体化干预,对改善宫颈癌肝转移患者的生存结局具有重要临床意义。本文系统回顾近年来相关文献,围绕病理类型、转移病灶特征、肿瘤分期、治疗方式及社会人群因素等方面,归纳并分析影响宫颈癌肝转移患者预后的关键因素,旨在为临床早期诊断与个体化治疗提供参考依据。
Abstract: Cervical cancer is one of the most common malignant tumors of the female reproductive system worldwide, ranking first in both incidence and mortality and posing a serious threat to women’s health. Hepatic metastasis from cervical cancer is a rare form of distant metastasis, which mostly occurs in the advanced stage of the disease or after tumor recurrence. Characterized by insidious onset, rapid progression, difficult treatment and extremely poor prognosis, it has become a major challenge in clinical management. Early identification of high-risk populations and timely implementation of individualized interventions are of great clinical significance for improving the survival outcomes of patients with hepatic metastasis of cervical cancer. By systematically reviewing relevant literature published in recent years, this article summarizes and analyzes the key prognostic factors for such patients from the perspectives of pathological type, metastatic lesion characteristics, tumor stage, treatment modalities and demographic factors, aiming to provide evidence for early clinical diagnosis and individualized treatment.
文章引用:张金怡, 姜向阳. 宫颈癌肝转移预后影响因素的研究进展[J]. 临床医学进展, 2026, 16(9): 52-58. https://doi.org/10.12677/acm.2026.1693019

参考文献

[1] 刁夏尧, 郭超, 金榆凯, 等. 中国癌症现状分析: 基于2024年全球流行病学数据[J]. 癌症, 2025, 44(7): 350-369.
[2] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263.
https://doi.org/10.3322/caac.21834
[3] Lei, J., Ploner, A., Elfström, K.M., Wang, J., Roth, A., Fang, F., et al. (2020) HPV Vaccination and the Risk of Invasive Cervical Cancer. New England Journal of Medicine, 383, 1340-1348.
https://doi.org/10.1056/nejmoa1917338
[4] Cohen, P.A., Jhingran, A., Oaknin, A. and Denny, L. (2019) Cervical Cancer. The Lancet, 393, 169-182.
https://doi.org/10.1016/s0140-6736(18)32470-x
[5] Liu, H., Ye, X., Li, D., Yao, Q. and Li, Y. (2021) Incidence, Clinical Risk and Prognostic Factors for Liver Metastasis in Patients with Cervical Cancer: A Population-Based Retrospective Study. BMC Cancer, 21, Article No. 421.
https://doi.org/10.1186/s12885-021-08127-6
[6] 谢尚丹, 胡群超, 诸海燕. 宫颈癌肝转移的治疗研究进展[J]. 临床肝胆病杂志, 2024, 40(7): 1307-1311.
[7] 丁鑫, 王乾印, 马亮亮, 等. 早期子宫颈癌患者术后发生肝转移的危险因素分析[J]. 中国妇幼健康研究, 2023, 34(6): 95-101.
[8] Hodgson, A., Olkhov-Mitsel, E., Howitt, B.E., Nucci, M.R. and Parra-Herran, C. (2019) International Endocervical Adenocarcinoma Criteria and Classification (IECC): Correlation with Adverse Clinicopathological Features and Patient Outcome. Journal of Clinical Pathology, 72, 347-353.
https://doi.org/10.1136/jclinpath-2018-205632
[9] Stolnicu, S., Hoang, L., Chiu, D., Hanko-Bauer, O., Terinte, C., Pesci, A., et al. (2019) Clinical Outcomes of HPV-Associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). American Journal of Surgical Pathology, 43, 466-474.
https://doi.org/10.1097/pas.0000000000001224
[10] Park, K.J. (2020) Cervical Adenocarcinoma: Integration of HPV Status, Pattern of Invasion, Morphology and Molecular Markers into Classification. Histopathology, 76, 112-127.
https://doi.org/10.1111/his.13995
[11] Ebrahim, N.A.A., Farghaly, T.A., El-Sherif, A.A., Fahmy, A.M., Othman, M.O., Tahoun, N.S., et al. (2025) Clinicopathological Insights and Management of Liver Metastases: Current Advances and Future Perspectives. World Journal of Hepatology, 17, Article ID: 110026.
https://doi.org/10.4254/wjh.v17.i10.110026
[12] Kim, G.E., Lee, S.W., Suh, C.O., Park, T.K., Kim, J.W., Park, J.T., et al. (1998) Hepatic Metastases from Carcinoma of the Uterine Cervix. Gynecologic Oncology, 70, 56-60.
https://doi.org/10.1006/gyno.1998.5037
[13] Yin, Z., Tang, H., Li, L., Ni, J., Yuan, S., Lou, H., et al. (2019) Impact of Sites versus Number of Metastases on Survival of Patients with Organ Metastasis from Newly Diagnosed Cervical Cancer. Cancer Management and Research, 11, 7759-7766.
https://doi.org/10.2147/cmar.s203037
[14] Lambert, A.W., Pattabiraman, D.R. and Weinberg, R.A. (2017) Emerging Biological Principles of Metastasis. Cell, 168, 670-691.
https://doi.org/10.1016/j.cell.2016.11.037
[15] Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., et al. (2017) Liver Sinusoidal Endothelial Cells: Physiology and Role in Liver Diseases. Journal of Hepatology, 66, 212-227.
https://doi.org/10.1016/j.jhep.2016.07.009
[16] Doll, K.M. (2018) Investigating Black-White Disparities in Gynecologic Oncology: Theories, Conceptual Models, and Applications. Gynecologic Oncology, 149, 78-83.
https://doi.org/10.1016/j.ygyno.2017.10.002
[17] Tangjitgamol, S., Levenback, C.F., Beller, U. and Kavanagh, J.J. (2004) Role of Surgical Resection for Lung, Liver, and Central Nervous System Metastases in Patients with Gynecological Cancer: A Literature Review. International Journal of Gynecological Cancer, 14, 399-422.
https://doi.org/10.1136/ijgc-00009577-200405000-00001
[18] Bacalbasa, N., Dima, S., Balescu, I., Brasoveanu, V. and Popescu, I. (2016) Liver Resection for Metachronous Hepatic Metastases from Cervical Cancer. HPB, 18, e692.
https://doi.org/10.1016/j.hpb.2016.01.081
[19] Kaseki, H., Yasui, K., Niwa, K., Mizuno, K., Inoue, T. and Ota, M. (1992) Hepatic Resection for Metastatic Squamous Cell Carcinoma from the Uterine Cervix. Gynecologic Oncology, 44, 284-287.
https://doi.org/10.1016/0090-8258(92)90059-r
[20] Yin, Z., Lou, H., Tang, H., Ni, J., Zhou, Q. and Chen, M. (2019) Efficacy of Radical Doses of Pelvic Radiotherapy for Primary Tumor Treatment in Patients with Newly Diagnosed Organ Metastatic Cervical Cancer. Radiation Oncology, 14, Article No. 82.
https://doi.org/10.1186/s13014-019-1297-x
[21] Li, H., Wu, X. and Cheng, X. (2016) Advances in Diagnosis and Treatment of Metastatic Cervical Cancer. Journal of Gynecologic Oncology, 27, e43.
https://doi.org/10.3802/jgo.2016.27.e43
[22] 殷卓敏. 盆腔放疗在ⅣB期宫颈癌治疗中的价值研究[D]: [博士学位论文]. 苏州: 苏州大学, 2020.
[23] Burd, E.M. (2003) Human Papillomavirus and Cervical Cancer. Clinical Microbiology Reviews, 16, 1-17.
https://doi.org/10.1128/cmr.16.1.1-17.2003
[24] Ge, Y., Zhang, Y., Zhao, K. and Zhu, H. (2022) Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer. Drug Design, Development and Therapy, 16, 3055-3070.
https://doi.org/10.2147/dddt.s374672
[25] Colombo, N., Dubot, C., Lorusso, D., Caceres, M.V., Hasegawa, K., Shapira-Frommer, R., et al. (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. New England Journal of Medicine, 385, 1856-1867.
https://doi.org/10.1056/nejmoa2112435
[26] Oaknin, A., Moore, K., Meyer, T., López-Picazo González, J., Devriese, L.A., Amin, A., et al. (2024) Nivolumab with or without Ipilimumab in Patients with Recurrent or Metastatic Cervical Cancer (Checkmate 358): A Phase 1-2, Open-Label, Multicohort Trial. The Lancet Oncology, 25, 588-602.
https://doi.org/10.1016/s1470-2045(24)00088-3
[27] Salem, J., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., et al. (2018) Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study. The Lancet Oncology, 19, 1579-1589.
https://doi.org/10.1016/s1470-2045(18)30608-9
[28] 王鹏焱, 林子又, 朱凯, 等. PD-1/PD-L1单抗药物抗肿瘤免疫治疗相关不良反应及超进展疾病研究进展[J]. 中国药理学与毒理学杂志, 2024, 38(1): 56-69.
[29] 吴红杨. 真实世界晚期宫颈癌免疫治疗疗效及影响因素分析[D]: [硕士学位论文]. 宜昌: 三峡大学, 2025.
[30] Tian, B., Han, C., Wang, H., Yan, L., Ding, Z., Liu, H., et al. (2023) Effect of Liver Metastasis on the Efficacy of Immune Checkpoint Inhibitors in Cancer Patients: A Systemic Review and Meta-Analysis. Clinical & Experimental Metastasis, 40, 255-287.
https://doi.org/10.1007/s10585-023-10217-7